Galderma MILITARY

Target: Galderma Group AG Research cut-off: 25 October 2026 Domain: Defence contracting, military supply chains, weapons systems, military logistics and occupation-related military infrastructure.

Direct Defence Contracting & Procurement

Corporate identity and activity

Galderma Group AG is a Switzerland-based dermatology company whose reported operations encompass Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology; its 2025 annual report describes these as its principal operating categories.¹

Galderma reported net sales of USD 5.207 billion for 2025, with growth across its three product categories, in its results announcement dated 5 March 2026.²

Its announcement dated 22 October 2026 reported USD 4.765 billion in sales for the first nine months of 2026 and continued growth in dermatological medicines, skincare and injectable aesthetics.³

Direct Israeli defence contracts

No public evidence identified establishing an awarded procurement contract between Galderma and the Israeli Ministry of Defence, IDF, Israel Prison Service, Border Police or another Israeli military or security institution.

Israeli defence procurement channels

The Israeli Ministry of Defence’s official procurement outreach identifies medical equipment and medicines as categories for which it seeks potential suppliers, but the reviewed page contains no Galderma-specific contract award or supplier identification.⁴

No public evidence identified of Galderma-specific IMOD tender numbers, contract values, framework agreements, security procurement awards or memoranda of understanding.

Defence trade directories

No public evidence identified establishing Galderma as an Israeli defence exporter, SIBAT-registered defence supplier or exhibitor marketing military products through Israeli defence exhibitions.

Defence cooperation announcements

No public evidence identified of a Galderma announcement describing an Israeli military partnership, defence joint venture, military research agreement or military supply programme.

Relevant commercial distinction

Galderma’s public global-presence information identifies healthcare and commercial operations in multiple international markets, including a Middle East regional presence; this geographical disclosure does not identify an Israeli defence establishment as a customer.⁵

Dual-Use Products & Tactical Variants

Civilian product portfolio

Galderma markets Restylane as a family of hyaluronic-acid fillers intended for aesthetic applications, including facial volume, contours and wrinkles.⁶

Galderma’s September 2026 clinical announcement describes Nemluvio (nemolizumab) as a treatment for moderate-to-severe atopic dermatitis, with clinical research examining skin lesions, itching, sleep disturbance and quality of life.⁷

Its 8 October 2026 announcement described further Nemluvio research involving atopic dermatitis and prurigo nodularis, including long-term clinical response data.⁸

On 15 October 2026, Galderma published additional Nemluvio clinical findings concerning children aged two to eleven with moderate-to-severe atopic dermatitis.⁹

Militarised variants

No public evidence identified of a Galderma product specifically modified, ruggedised, militarised or developed to meet IDF equipment specifications.

Civilian versus military medical applications

Galderma’s published Restylane and Nemluvio materials describe civilian aesthetic and therapeutic applications; those documents do not identify an Israeli military end-user or military-specific variant.^{6, 8}

No public evidence identified of Galderma medical products being furnished under a documented Israeli military healthcare contract.

Weapons-related software and AI

Galderma’s September 2026 presentation programme describes research on dermatological conditions, skin longevity and patient outcomes, without identifying a weapons-targeting or fire-control application.¹⁰

No public evidence identified of Galderma developing autonomous targeting software, military fire-control AI, precision weapons guidance or other software purpose-built to generate kinetic effects.

Export licensing and end-use certification

No public evidence identified of an Israeli military end-user certificate, military-purpose export licence, defence-equipment classification or weapons-related export-control review concerning Galderma.

Heavy Machinery, Construction & Infrastructure

Manufacturing and operational footprint

Galderma describes its international operational footprint through offices, research and development facilities and manufacturing sites serving its dermatology activities.⁵

Its corporate description identifies its business as the development and commercialisation of dermatological products and treatments.¹¹

Equipment in occupied territories

No public evidence identified documenting Galderma-owned machinery, construction equipment or vehicles participating in settlement construction, checkpoint construction, demolitions or separation-barrier works in the occupied West Bank, East Jerusalem or Golan Heights.

Direct and indirect supply

No public evidence identified of Galderma providing construction equipment to Israeli military engineering units, civil administration contractors or settlement infrastructure operators, either directly or through distributors.

Construction and engineering contracts

No public evidence identified of contracts involving Galderma for Israeli military bases, checkpoints, security roads, detention infrastructure, settlement expansion or barrier maintenance.

Settlement database context

A Business & Human Rights Resource Centre publication dated 25 September 2026 records OHCHR’s updated database of businesses involved in specified Israeli settlement-related activities, reporting 214 listed companies from 11 countries.¹²

No public evidence identified establishing Galderma’s inclusion in that database or identifying a Galderma-specific construction or infrastructure relationship with a settlement.

Supply Chain Integration with Defence Primes

Corporate ownership background

The Abu Dhabi Investment Authority records that a consortium involving ADIA and EQT acquired Galderma from Nestlé in October 2019 for CHF 10.2 billion.¹³

Galderma announced on 8 December 2025 that L’Oréal intended to increase its equity interest by purchasing another 10% from a shareholder consortium involving EQT, Abu Dhabi Investment Authority and Auba Investment Pte. Ltd.¹⁴

L’Oréal independently announced the additional investment on 8 December 2025, describing the intended increase to a 20% shareholding as a strategic investment in dermatology and aesthetics.¹⁵

Galderma confirmed in September 2026 that L’Oréal held 20% of its shares and approximately 80% were in free float.¹⁶

Relationship to Israeli defence manufacturers

No public evidence identified of Galderma supplying Elbit Systems, Israel Aerospace Industries, Rafael Advanced Defense Systems or another Israeli defence prime with weapons components, specialist materials, manufacturing services or subsystems.

Component categories

No public evidence identified of Galderma producing guidance electronics, communications equipment, optical targeting systems, propulsion components, armour materials, radar assemblies or military structural components for Israeli defence contractors.

Joint development and co-production

No public evidence identified of Galderma participating in an Israeli military technology-transfer agreement, weapons-development project, defence co-production arrangement or military industrial research programme.

Principal shareholder attribution

The documented L’Oréal investment establishes substantial share ownership in Galderma, but the reviewed primary announcements concern dermatology-related investment and scientific collaboration and do not describe a transaction supplying Galderma products to Israeli armed forces.^{14, 15}

No public evidence identified of a military-channel transfer to an Israeli defence company attributable to Galderma through a controlling shareholder or personal investment vehicle.

Board and executive relationships

Galderma’s current governance disclosure identifies Thomas Ebeling as Chair, Sherilyn McCoy as Vice-Chair, and Flemming Ørnskov among its directors, together with Dan Browne, Maria Teresa Hilado, Harry Kirsch, Karen Ling, Roberto Marques, Samuel du Retail and Delphine Viguier-Hovasse.¹⁷

Galderma’s published biography of CEO Flemming Ørnskov identifies previous executive positions at Shire, Bayer, Novartis and Merck, and a non-executive chairmanship at Waters Corporation.¹⁸

The company’s 2026 AGM announcement described the proposed replacement of Michael Bauer and Marcus Brennecke, who represented the EQT-led consortium, with L’Oréal-associated nominees Delphine Viguier-Hovasse and Samuel du Retail.¹⁹

No public evidence identified of a Galderma controlling principal directing a Galderma-related military procurement programme, holding a documented Galderma-linked Israeli defence directorship or financing a specific Israeli weapons programme through Galderma.

No public evidence identified of relevant FIDF donations, reservist-fund transfers or military-specific charitable matching commitments by Galderma’s named controlling principals.

Logistical Sustainment & Base Services

Military installation services

No public evidence identified of Galderma holding contracts for IDF base maintenance, catering, fuel, transportation, telecommunications, waste management, warehousing or related military installation services.

Medical service provision

The Israeli Ministry of Defence publicly solicits potential vendors offering medicines and medical equipment, but that general procurement invitation does not establish Galderma as a vendor or identify a Galderma supply contract.⁴

No public evidence identified establishing Galderma as a contractual pharmaceutical supplier to an IDF base, military medical centre, military detention facility or other Israeli state-security installation.

Geographic specificity

No public evidence identified of Galderma military logistics operations at Israeli installations in the occupied West Bank, East Jerusalem, Golan Heights or Negev.

Shipping and freight

No public evidence identified of Galderma contracting to transport Israeli military cargo, weapons, ammunition or defence equipment through Israeli ports, airports or freight networks.

Military-use distribution

No public evidence identified of a Galderma-specific military shipment, military end-user declaration, defence consignment number or customs entry identifying an Israeli armed-forces consignee.

Reservist and employee military policies

No public evidence identified of a Galderma policy specifically subsidising Israeli military reservist service, financing military units or providing corporate support services to serving Israeli military personnel.

Munitions, Weapons Systems & Strategic Platforms

Lethal platforms

Galderma’s 2025 annual report identifies Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology as its operating categories, while the October 2026 commercial update describes continuing sales and research activity in those categories.^{1, 3}

No public evidence identified of Galderma manufacturing or supplying firearms, artillery, armoured vehicles, combat drones, naval weapons, missiles or other lethal military platforms to Israel.

Munitions and precursors

No public evidence identified of Galderma manufacturing or exporting ammunition, explosives, chemical propellants, warhead assemblies or specialised munitions precursor materials for Israeli military end-users.

Strategic defence systems

No public evidence identified linking Galderma to Iron Dome, David’s Sling, Arrow, Israeli combat aircraft, main battle tanks, warships or ballistic missile programmes.

Sub-systems

No public evidence identified of Galderma supplying weapons guidance modules, fire-control equipment, military radar components, propulsion units, strategic communications modules or military sensor assemblies.

Purpose-built weapons software

No public evidence identified of Galderma participating in autonomous targeting, military kill-chain automation, precision weapons integration or other software programmes primarily designed to produce a targeting decision or weapons effect.

Export Licensing, Regulatory & Legal History

Regulatory distinction

The Israeli Ministry of Health describes a civilian cosmetics regulatory framework under which marketed cosmetics may be recorded through licensing or marketing notifications, with public searches available by manufacturer, importer and product identifiers.²⁰

This civilian regulatory framework does not constitute an Israeli military procurement record or defence export authorisation.²⁰

Military export licences

No public evidence identified of a government granting, refusing, suspending or revoking an arms-related export licence specifically concerning Galderma supplies to Israeli military or security end-users.

Military end-user certification

No public evidence identified of a Galderma-specific Israeli military end-user certificate, classified procurement authorisation or defence export-control determination.

Sanctions and embargo enforcement

No public evidence identified of enforcement proceedings against Galderma for violating an arms embargo, military export restriction or defence-related sanctions concerning Israel.

Judicial proceedings

No public evidence identified of litigation naming Galderma as a supplier of Israeli weapons, military logistics equipment or occupied-territory security infrastructure.

Constructive-notice dates

No public evidence identified establishing a relevant Galderma military or settlement-infrastructure contract continuing after 19 July 2024 or November 2024.

No public evidence identified of Galderma receiving a defence-supply-specific shareholder resolution, employee petition, sanctions notification or NGO demand concerning an established Israeli military contract.

Civil Society Scrutiny & Documented Investigations

UN and civil-society investigations

The September 2026 OHCHR settlement-database update, as reported by the Business & Human Rights Resource Centre, describes a database examining specified business activities connected with Israeli settlements and states that the updated list contained 214 companies.¹²

No public evidence identified in the reviewed material establishing Galderma as a named company involved in Israeli settlement infrastructure, military procurement or defence-industrial production.

Defence-specific NGO investigations

No public evidence identified of a published Who Profits, AFSC Investigate, Amnesty International, Human Rights Watch, Al-Haq or comparable investigation documenting a particular Galderma contract with the Israeli military-industrial sector.

Boycott and divestment activity

No public evidence identified of a defence-sector-specific institutional divestment decision, organised boycott campaign or shareholder resolution directed at Galderma over a verified Israeli weapons or military logistics contract.

Corporate responses

No public evidence identified of Galderma publicly announcing the cancellation of an Israeli military contract, termination of a weapons-related partnership or introduction of military export end-use monitoring following civil-society pressure.

Commercial continuity

Galderma’s October 2026 financial announcement documents continuing international commercial operations and growth in its dermatology businesses, without identifying Israeli military end-users.³

No public evidence identified demonstrating that Galderma continued a documented military supply or occupied-territory infrastructure relationship after either the July 2024 ICJ advisory-opinion date or the November 2024 ICC arrest-warrant date.